A systematic review and meta-analysis of 18F-labeled amyloid imaging in Alzheimer’s disease by Yeo, Jing Ming et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A systematic review and meta-analysis of 18F-labeled amyloid
imaging in Alzheimer’s disease
Citation for published version:
Yeo, JM, Waddell, B, Khan, Z & Pal, S 2015, 'A systematic review and meta-analysis of 18F-labeled
amyloid imaging in Alzheimer’s disease' Alzheimer's & Dementia: Diagnosis, Assessment & Disease
Monitoring, vol. 1, no. 1, pp. 5-13. DOI: 10.1016/j.dadm.2014.11.004
Digital Object Identifier (DOI):
10.1016/j.dadm.2014.11.004
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
Publisher Rights Statement:
(c) 2015 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article
under the CC BY-NC-ND 4.0 license
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 5–13Neuroimaging
A systematic review and meta-analysis of 18F-labeled amyloid imaging
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eDepartment of Neurology, Forth Valley Royal Hospital, NHS Forth Valley, Larbert, UKAbstract Background: Amyloid imaging using fluorine 18–labeled tracers florbetapir, florbetaben, and flute-*Corresponding a
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creativecommons.org/metamol has recently been reported in Alzheimer’s disease (AD).
Methods: We systematically searched MEDLINE and EMBASE for relevant studies published from
January 1980 to March 2014. Studies comparing imaging findings in AD and normal controls (NCs)
were pooled in a meta-analysis, calculating pooled weighted sensitivity, specificity, and diagnostic
odds ratio (OR) using the DerSimonian-Laird random-effects model.
Results: Nineteen studies, investigating 682 patients with AD, met inclusion criteria. Meta-analysis
demonstrated a sensitivity of 89.6%, a specificity of 87.2%, and an OR of 91.7 for florbetapir in differ-
entiating AD patients from NCs, and a sensitivity of 89.3%, a specificity of 87.6%, and a diagnostic
OR of 69.9 for florbetaben. There were insufficient data to complete analyses for flutemetamol.
Conclusions: Results suggest favorable sensitivity and specificity of amyloid imaging with fluorine
18–labeled tracers in AD. Prospective studies are required to determine optimal imaging analysis
methods and resolve outstanding clinical uncertainties.
 2015 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Alzheimer’s; Dementia; Amyloid; Positron emission tomography; Florbetapir; Florbetaben; Flutemetamol; Sensi-tivity; Specificity1. Introduction
Timely diagnosis of dementia obviates prolonged uncer-
tainty, unnecessary investigations, delays in initiation of
symptomatic treatments, and recruitment of poorly charac-
terized patients into research trials. Definitive diagnosis
may only be achieved by histopathological examination of
invasive brain biopsy or postmortem tissue, or molecular ge-
netic testing in a minority with inherited dementia. Clinical
diagnostic criteria in recent use for Alzheimer’s disease
(AD) often fail to robustly differentiate accurately betweenuthor. Tel.: 144-07940 230846; Fax: +44-131 242
vankar.pal@ed.ac.uk
16/j.dadm.2014.11.004
blished by Elsevier Inc. on behalf of the Alzheimer’s Associ
licenses/by-nc-nd/4.0/).AD and non-AD pathology with up to 40% of patients diag-
nosed with non-AD dementias identified as having pathol-
ogy consistent with AD at postmortem in some series [1].
Clinical diagnosis either provides good diagnostic sensi-
tivity at the expense of specificity or vice versa (pooled av-
erages 81% sensitive and 70% specific) [2].
When considering the pathophysiology of AD, it has been
proposed that the presymptomatic phase is characterized by
an early rise in amyloid accumulation, followed later by syn-
aptic dysfunction, tau-mediated neuronal injury, reduction in
brain volume, and finally emergence of cognitive symptoms,
followed by a clinical syndrome of frank dementia [3]. This
suggests a sensitive and specific biomarker of brain amyloid
deposition, such as amyloid imaging, would be a useful diag-
nostic tool, perhaps as an adjunct to investigation ofation. This is an open access article under the CC BY-NC-ND license (http://
J.M. Yeo et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 5–136cerebrospinal fluid (CSF) biomarkers (including amyloid
and tau), cerebral hypometabolism ascertained by 18F-
fluorodeoxyglucose positron emission tomography, hippo-
campal volume, tractography, and clinical cognitive
assessments.
The most widely studied radiolabeled amyloid ligand,
11C-labeled Pittsburgh compound B (11C-PiB), demon-
strates high affinity and selective amyloid binding. Imaging
using 11C-PiB has been reported to successfully differentiate
between patients with AD and healthy controls [4], predict
the progression of mild cognitive impairment (MCI) to
symptomatic AD [5], and correlate with underlying amyloid
neuropathology [6]. Disadvantages include a radioactive
decay half-life of only 20 minutes and a scanning time of
30 minutes, rendering it limited to use in centers with cyclo-
trons, which are expensive and impractical, thereby limiting
its utility in clinical settings.
The proven efficacy of amyloid imaging and impractical-
ities of 11C-PiB triggered a search to identify compounds
with desirable qualities of high affinity for amyloid, rapid
brain uptake and washout from non–amyloid-containing tis-
sues, short imaging time, and long stable pseudoequilibrium
allowing flexibility in imaging acquisition time. Amyloid
imaging using three novel fluorine 18–labeled (18F) tracers,
18F-florbetapir, 18F-florbetaben, and 18F-flutemetamol, with
a longer half-life than 11C-PIB of 110 minutes has recently
been investigated in a number of studies, including phase 2
clinical trials. These agents have recently gained US Food
and Drug Administration approval for use in clinical prac-
tice. The benefits of identifying amyloid in vivo extend to
monitoring disease progression, and, with the advent of
treatments targeting amyloid deposition, potentially also as
a surrogate biomarker of treatment efficacy.
In this systematic review and meta-analysis, we (1) assess
the quality of recent studies investigating amyloid imaging
using novel fluorine-labeled tracers, (2) investigate their
pooled reported sensitivity and specificity for diagnosis of
AD, and (3) consider the utility of amyloid imaging using
these agents in the differential diagnosis of dementia
syndromes.2. Methods
2.1. Search strategy and study selection
We searched the Medical Literature Analysis and
Retrieval System Online (MEDLINE) and the Excerpta
Medica Database (EMBASE) via OVID for human studies
published from January 1980 to March 2014, inclusive of
all languages. The search terms used were (1) “dementia,”
(2) “amyloid” or “positron emission tomography,” (3) “flor-
betapir” or “florbetaben” or “flutemetamol,” and (3) “sensi-
tivity” and “specificity” or “diagnosis.” The inclusion
criteria were as follows: (1) original study; (2) study of diag-
nostic accuracy of florbetapir/florbetaben/flutemetamol am-
yloid imaging; (3) the study compares clinically orpathologically diagnosed dementia (AD, frontotemporal de-
mentia [FTD], vascular dementia [VD], dementia with Lewy
bodies [DLB) with each other or with normal controls;
(4) amyloid imaging was not interpreted with other imaging
modality; (5) total subjects in the study of at least 10; and
(6) sufficient data were reported to enable a 2 ! 2 contin-
gency table to be formulated for the calculation of sensitivity
and specificity. Two authors applied these inclusion criteria
independently in identifying the studies.
2.2. Data extraction
We extracted data on the author’s name, year of publica-
tion, amount of ligand injected per scan, method of image
analysis, criteria used for defining a positive amyloid scan,
criteria used for clinical or pathological diagnosis, study
population characteristics (mean age, mean Mini-Mental
State Examination [MMSE] score), internal and external
validity score, and constructed a 2 ! 2 contingency table
for each study. (1) True positive was defined as patients
with AD who had positive amyloid imaging, (2) false nega-
tive: patients with AD who had negative amyloid imaging,
(3) true negative: diagnostic comparison group patients
with negative amyloid imaging, and (4) false positive: diag-
nostic comparison group patients with positive amyloid im-
aging. In studies where there were more than one relevant
data set, we chose the data set with (1) the most relevant clin-
ical diagnosis (probable and definite AD, as opposed
to possible AD), (2) quantitative analysis, rather than visual
analysis, (3) age-matched normal controls (NCs) (when
there were both young and older normal controls), and
(4) data set in which intermediate result was reported.
2.3. Quality assessment
Our study is reported in accordance with the PRISMA
guidelines; a completed PRISMA checklist is available as
Appendix 1 [7]. Our assessment of the internal and external
validity of individual studies is detailed in Appendix 2;
assessment was based on the STARD checklist, and in
particular items 3 to 5, 7, 11 to 13, 15, 16, 18, 21, 22, and
25 [8].
2.4. Data synthesis and statistical analysis
We calculated the sensitivity and specificity of the rele-
vant diagnostic comparison groups for each included study.
We also pooled the studies comparing amyloid imaging in
AD patients and NCs for florbetapir and florbetaben in a
meta-analysis using Meta-DiSc (Javier Zamora, Boston,
MA, USA) software for statistical analysis [9]. For this,
we calculated the pooled weighted sensitivity, specificity,
positive and negative likelihood ratios (LRs), and diagnostic
odds ratio (OR) for AD patients versus NC using
DerSimonian-Laird random-effects model. This model rec-
ognizes both between- and within-study heterogeneity and
considers the different effect sizes of the studies, thus
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[10]. For the log OR of any 2! 2 table with zero, the soft-
ware would add 0.5 to each cell. We assessed for between-
study heterogeneity using I2 and c2 test, where an I2
.50% and a P value ,.05 indicate a significant amount of
heterogeneity unlikely to be explained by random variation
alone [11]. We further investigated the heterogeneity using a
summary receiver operating characteristic curve to describe
a set of operating characteristics across the studies and used
Spearman correlation coefficient to look for a threshold ef-
fect. A positive Spearman correlation coefficient between
logit of sensitivity and logit of 12 specificity would suggest
the possibility of a threshold effect, caused by the different
studies using different diagnostic thresholds to determine a
positive or negative result. We also used single-factor
meta-regression analysis to look for possible sources of
heterogeneity using the following variates as predictor vari-
ables: (1) mean age; (2) meanMMSE score; (3) male-female
distribution; and (4) method of image analysis (visual vs.
quantitative). A variate is considered to be explanatory if
the regression coefficient was statistically significant
(P , .05).3. Results
Our literature search produced a total of 86 articles
(Fig. 1). We excluded 66 articles after reading the abstracts
and reviewed the remaining 23 full-text articles, after which
a further six articles were excluded. We identified two addi-
tional articles from reviews and references, bringing the re-
view to a total of 19 articles. Table 1 summarizes the number
and mean age of subjects in the included studies. Table 2
specifies the data collected from each study. The review re-
vealed that most of the available studies’ diagnostic compar-
ison groups were AD patients versus NCs; therefore, we
performed a meta-analysis investigating these groups. Rele-
vant data pertaining to other dementias were also included
for the consideration of diagnostic utility (Table 2).
Table 3 summarizes the pooled weighted sensitivity, speci-
ficity, LRs, and diagnostic ORs for AD patients versus
NCs for florbetapir and florbetaben. The pooled diagnostic
ORs and positive LRs and their confidence intervals (CIs)
were all above 1, suggesting that florbetapir and florbetaben
amyloid imaging have diagnostic utility in this group.3.1. Florbetapir
There were 10 studies identified in this group, with nine
studies comparing the diagnostic utility of AD versus NC
and one study comparing AD versus non-AD (which
included FTD, VD, alcohol-related dementia, corticobasal
degeneration, depression, structural causes, and dementia
of uncertain etiology). Two studies, Clark et al. [13] and
Doraiswamy et al. [15], were prospective cohort studies,
whereas the rest were case-control studies. The study by
Clark et al. was the only one with a neuropathological diag-nosis, demonstrating a very favorable sensitivity of 97.5%
and specificity of 100% in differentiating AD patients
from NCs. Fleisher et al. [16], Fleisher et al. [17], Doraisw-
amy et al. [15], and Grundman et al. [18] recruited patients
from the same multicenter nonrandomized phase I and II tri-
als of florbetapir PET imaging; therefore, only the study by
Fleisher et al. [16] with the most complete number of pa-
tients was included in the meta-analysis for AD patients
versus NCs.
For the meta-analysis, seven studies were included, with a
total number of 181 patients with AD (combined mean age,
71.8 years [95% CI: 67.4–76.2], combined mean MMSE
score, 21.0 [95% CI: 18.7–23.1]) and 197 NCs (combined
mean age, 68.3 years [95% CI: 64.5–72.2], combined
mean MMSE score, 29.2 [95% CI: 28.8–29.6]). The meta-
analysis revealed a pooled weighted sensitivity of 89.6%, a
pooled weighted specificity of 87.2%, and a pooled diag-
nostic OR of 91.7 for differentiating AD patients from
NCs. For the pooled diagnostic OR, heterogeneity was pre-
sent between the studies, and although the CI did not contain
the value of 1, it was wide, suggesting that more studies with
larger sample sizes are required for a more definite conclu-
sion on the strength of this diagnostic utility. Spearman cor-
relation coefficient was 20.927 (P 5 .003) suggesting the
absence of a threshold effect. Single-factor meta-regression
analysis for other possible sources of heterogeneity did not
show any significant association between the variates
described previously and log OR. This heterogeneity may
contribute to an underestimation of the discriminatory abil-
ity of florbetapir.3.2. Florbetaben
Six case-control studies were identified in this group.
Barthel et al. [24] reported on the use of florbetaben
PET imaging in a multicenter phase II trial in patients
with AD and NCs, finding a sensitivity of 85% and a spec-
ificity of 91%. It found that regional standard uptake value
ratios (SUVRs) were significantly higher in the frontal,
temporal, parietal, occipital, and anterior and posterior
cingulate cortices in patients with AD compared with
NCs. An ongoing phase III trial on florbetaben PET imag-
ing for detecting in vivo b-amyloid using histopathology as
the gold standard is estimated to be completed later this
year [33]. Schipke et al. [25] and Tiepolt et al. [26] re-
cruited patients from the phase II trial and were therefore
excluded from the meta-analysis.
For the meta-analysis, four studies were included, with a
total number of 131 patients with AD (combined mean age,
70.6 years [95% CI: 67.9–73.3], combined mean MMSE
score, 21.8 [95% CI: 19.2–24.3]) and 121 NCs (combined
mean age, 69.1 years [95% CI: 66.3–71.9], combined
mean MMSE score, 29.4 [95% CI: 29.0–29.8]). The meta-
analysis resulted in a pooled weighted sensitivity of
89.3%, a pooled weighted specificity of 87.6%, and a pooled
diagnostic OR of 69.9, with no significant heterogeneity (all
Fig. 1. Flow chart of study selection.
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diagnostic OR again suggests the need for further and larger
studies to be conducted.
3.3. Flutemetamol
Therewere three studies in this group, with the study byNe-
lissen et al. [32] being a phase I trial and the study by Vanden-
berghe et al. [31] being a phase II trial for flutemetamol PET
imaging inAD.Resultswere encouraging,with thephase II trial
demonstrating a sensitivity of 92.6%and specificity of 96.0% in
differentiatingADpatients fromNCs. The study byDuara et al.
[30] was an extension of the phase II trial, which demonstrated
the additive value of structural magnetic resonance imaging to
the diagnostic classification of prodromal and probable AD.
Flutemetamol is structurally identical to 11C-PiB except for
the presence of 30 18F-fluorine, making it unique compared to
the other fluorine tracers. A trial is ongoing on the distributionTable 1
Summary of all studies
Amyloid imaging Number of studies
Alzheimer’s disease
Number Combined mea
Florbetapir 10 343 72.5 (68.2–76.
Florbetaben 6 277 70.7 (68.2–73.
Flutemetamol 3 62 69.3 (67.1–71.
Abbreviation: CI, confidence interval.of 11C-PiB and flutemetamol in regions of cerebral amyloid
deposition in AD, with the hypothesis that there will be no sig-
nificant difference between the two [34].
4. Discussion
Clinical diagnostic criteria in recent use for AD
(including iterations of the Diagnostic and Statistical
Manual of Mental Disorders and International Classification
of Diseases) have variable specificity and sensitivity with
pooled averages of 70% and 81%, respectively, when
compared with postmortem data [2]. The National Institute
on Aging and the Alzheimer’s Association work groups
have recently revised the NINCDS-ADRDA criteria for
AD to incorporate biomarkers in an attempt to improve diag-
nostic accuracy [35]. A dynamic change in biomarker pro-
files during the evolution of AD progression has been
postulated with early deposition of b-amyloid followed byNon–Alzheimer’s disease
n age, y (95% CI) Number Combined mean age, y (95% CI)
8) 348 68.2 (64.5–71.9)
2) 253 68.5 (66.0–71.1)
4) 38 66.6 (62.3–71.0)
Table 2
Characteristics of individual studies
tudy Year
Quality* Imaging method Diagnosis Study population Outcome measure
Internal External
Amount
MBq
Image
analysis
Definition positive
amyloid scan
SUVR threshold
Diagnostic
criteria Number
Mean
age (SD)
Mean
MMSE
(SD) Male/female
Sensitivity
(%)
Specificity
(%)
lorbetapir
Camus et al. [12] 2012 9 4 259 6 57 Quantitative .1.122 NINCDS, DSM-IV 13 AD 67.8 (6.5) 23.0 (3.6) 4/9 92.3 90.5
21 NC 66.2 (4.3) 29.0 (1.3) 9/12
Clark et al. [13,14] 2012 9 3 370 Quantitative .1.10 Pathological 39 AD All 79.4
(12.6)
NR NR 97.4 100
10 NC
Doraiswamy et al. [15] 2012 9 4 370 Visual Cortical uptake NINCDS,
MMSE24
31 AD 76.7 21.4 28/41 67.7 85.5
69 NC 69.8 29.6 18/13
Fleisher [16] 2011 9 4 370 Quantitative 1.17 NINCDS, M10-24 68 AD 74.6 (9.5) 19.9 (4.4) 16/33 80.9 79.3
82 NC 71.8 (10) 29.6 (0.5) 10/45
Fleisher et al. [17] 2013 9 4 370 Quantitative .1.083 NINCDS, M10-24 45 AD 74.7 (9.0) 20.6 (4.3) 22/23 84 75.4
61 NC 67.9 (11.3) 29.6 (0.5) 27/34
Grundman et al. [18] 2013 9 2 370 Visual NR Clinical judgment 86 AD NR NR NR 61.6 57.1
21 non-AD
Joshi et al. [19] 2012 9 4 370 Visual Cortical uptake NINCDS, M10-24 9 AD 70.3 20.9 2/8 100 100
11 NC 44.4 29.7 6/4
La Joie et al. [20] 2012 9 3 4 MBq/kg Quantitative .1.1 NINCDS 22 AD NR NR NR 90.9 91.9
37 NC
Newberg et al. [21] 2012 9 3 370 Visual Cortical uptake NINCDS 19 AD 73 (9) 20 (7) 8/11 94.7 95.2
21 NC 67 (13) 29 (1) 13/8
Wong et al. [22] 2010 9 2 370 Visual Cortical uptake NINCDS, M10-24 11 AD NR NR NR 90.9 86.7
15 NC
lorbetaben
Barthel et al. [23] 2011 9 3 300 Visual Cortical uptake NINCDS, DSM-IV 10 AD 69 (7) 19 (7) 8/2 90 90
10 NC 67 (8) 29 (1) 8/2
Barthel et al. [24],
phase II trial
2011 9 4 300 Quantitative Linear discriminate
function analysis
of regional SUVRs
NINCDS, DSM-IV 81 AD 70.7 (7.8) 22.6 (2.3) 47/34 85 91
69 NC 68.2 (6.9) 29.3 (0.8) 30/39
Schipke et al. [25] 2012 9 3 NR NR NR NINCDS, DSM-IV 121 AD,
80 NC
NR NR NR 81.8 82.5
Tiepolt et al. [26] 2012 9 3 300 6 60 Visual Cortical uptake NINCDS, DSM-IV 25 AD 70.9 (8.0) 22.5 (2.2) 14/11 80 96
25 NC 67.1 (7.7) 29.2 (0.8) 14/11
Villemagne et al.
[27,28]
2011 9 4 300 Visual Cortical uptake NINCDS,
Consensus
criteria FTD
30 AD 72.0 (9.2) 22.8 (3.7) 14/16
32 NC 70.7 (6.3) 29.6 (0.7) 19/13 96.7 84.4
11 FTD 63.5 (7.0) 24.5 (2.9) 7/4 96.7 90.9
7 DLB 71.7 (5.7) 24.0 (6.6) 7/0 96.7 71.4
4 VD 73.0 (11.0) 27.8 (2.1) 0/4 96.7 75.0
5 PD 72.6 (6.5) 27.4 (2.7) 5/0 96.7 100
Villemagne et al. [29] 2012 9 4 300 Visual Cortical uptake NINCDS 10 AD 70.8 (9.6) 22.7 (3.9) 8/2 100 70
10 NC 70.4 (7.2) 29.6 (0.7) 6/4
lutemetamol
Duara et al. [30] 2013 9 4 185 Quantitative .1.56 NINCDS, DSM-IV 27 AD 69.6 (7.0) 23.3 (2.2) 12/15 92.6 93.3
.1.40 15 NC 68.7 (7.6) 28.8 (1.0) 9/6 92.6 80
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J.M. Yeo et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 5–1310neuronal degeneration [3]. Cerebral PET amyloid imaging
uses tracers that bind to fibrillar b-amyloid plaques and is
able to estimate neuritic amyloid plaque burden [4]. This
is the first systematic review and meta-analysis to investigate
the diagnostic utility of florbetapir, florbetaben, and fluteme-
tamol as biomarkers of amyloid deposition in AD.
Our results demonstrate a pooled weighted sensitivity of
89.6%, a pooled weighted specificity of 87.2%, and a pooled
diagnostic OR of 91.7 for florbetapir in differentiating AD
patients from NCs. Investigation of florbetaben demon-
strated similar results with a pooled weighted sensitivity of
89.3%, a specificity of 87.6%, and a pooled diagnostic OR
of 69.9. There were insufficient data to provide pooled statis-
tical analysis of the diagnostic utility of flutemetamol. These
results therefore suggest favorable sensitivity and specificity
of fluorine-based tracers when compared to clinical diag-
nosis and other biomarkers commonly used in practice
[21] and are comparable to 11C-PiB imaging, with, in addi-
tion, good patient tolerability demonstrated [23]. When
considering the pooled diagnostic OR, heterogeneity was
present between studies, with wide CIs suggesting the
need for more and better powered studies. All the studies as-
sessed had good internal validity, reflecting that a causal
relationship has been satisfactorily demonstrated and that
confounding factors were controlled for as far as possible.
There are, however, a number of important limitations in
studies evaluated in this systematic review which must be
considered before it can be concluded that amyloid imaging
with fluorine-based tracers should be introduced as a routine
in the investigation of suspected AD. Although all studies
scored highly on measures of internal validity, 10 studies
did not score maximum points on external validity; most
of these did not report on comorbidities and exclude patients
accordingly. The number of subjects included in each study
was low, and the number of studies per tracer was limited
(Table 2), most notably in the flutemetamol group. Different
diagnostic criteria were applied across the studies, adding to
interstudy heterogeneity. Pharmaceutical funding of
included studies may feasibly have introduced bias.
Characterization of cognitive impairment was variable
and somewhat limited in most studies, with MMSE reported
in the majority. MMSE is notably easy to administer with
high test-retest reliability but lacks diagnostic specificity in
AD [36], as demonstrated by the overlap of MMSE scores
between those diagnosed with MCI and healthy controls
[30] and those with AD and MCI [27]. Some of the studies
did use more detailed cognitive batteries, but details of re-
sults are not reported in sufficient detail to allow evaluation
in a meta-analysis [19,23,26,29].
Only one study correlated imaging findings with histo-
pathological confirmation of AD at postmortem [13],
demonstrating a high sensitivity and specificity of 92%
and 100%, respectively, for florbetapir. Although these re-
sults are encouraging, study inclusion criteria required a pre-
dicted life expectancy of less than 6 months, limiting
generalizability of these results.
Table 3
Summary of pooled weighted sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio for Alzheimer’s disease versus normal
controls
Sensitivity (%) Specificity (%) LR1 LR2 Diagnostic OR
Florbetapir (n 5 7)
Pooled estimates 89.6 87.2 7.90 0.108 91.7
95% CI 84.2–93.6 81.7–91.6 4.23–14.8 0.055–0.213 26.7–315
I2 value, % 46.2 50.3 38.9 35.7 53.5
Chi-squared (P value) 11.2 (P 5 .084) 12.1 (P 5 .060) 9.82 (P 5 .132) 9.34 (P 5 .155) 12.9 (P 5 .045)
Florbetaben
Pooled estimates 89.3 87.6 6.06 0.141 69.9
95% CI 82.7–94.0 80.4–92.9 3.36–10.9 0.087–0.228 29.6–165
I2 value, % 48.6 13.4 34.8 0.0 0.0
Chi-squared (P value) 5.83 (P 5 .120) 3.46 (P 5 .326) 4.60 (P 5 .203) 2.61 (P 5 .456) 0.68 (P 5 .879)
Abbreviations: LR1, positive likelihood ratio, LR2, negative likelihood ratio; OR, odds ratio; CI, confidence interval.
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loid deposition and for the development of AD. APOE ε4
status was demonstrated to significantly influence amyloid
imaging results [12,17,24] (with Camus et al. [12] demon-
strating this as the only significant variable). Reporting of
APOE ε4 status was incomplete across studies, and no statis-
tical adjustment was made for results. Furthermore, the sig-
nificance of amyloid deposition in asymptomatic APOE ε4–
positive individuals remains extremely uncertain because of
a lack of longitudinal data on natural history in such cases.
A fundamental limitation of amyloid imaging is the lack
of specificity of amyloid burden in AD. Amyloid deposition
has been implicated in a range of neurodegenerative disor-
ders, including common differential diagnoses for AD,
such as DLB and some pathological subtypes of primary
progressive aphasia. Villemagne et al. [27] investigated the
potential of amyloid imaging in differentiating between pa-
tients with FTDs, VD, DLB, Parkinson’s disease, MCI, and
healthy controls. Differences were only demonstrated be-
tween AD and healthy controls (and MCI and healthy con-
trols). Because of small numbers in the subgroup analyses,
robust conclusions cannot be drawn about the role of these
tracers in the differential diagnosis of dementia without
further clarification from larger and better powered studies.
Methods for scan interpretation differed between studies
evaluated in this meta-analysis and included visual and
quantitative analysis (Table 2). Although quantitative image
analysis should feasibly provide a more objective outcome
measure, SUVR cutoff varied, with only one study using a
SUVR cutoff calculated from patients with postmortem-
proven AD and healthy APOE ε4 negative as controls (Fle-
isher et al. [16]). Visual interpretation varied between
studies, with Camus et al. [12] reporting 31% specificity
for AD; however, Clark et al. [13] demonstrated a strong cor-
relation between visual review of images and histopatholog-
ical diagnosis.
Results from our meta-analysis do not enable recommen-
dations to be made regarding transformation of MCI to AD
in clinical practice. Doraiswamy et al. [15] provide limited
longitudinal data to address this question with a suggestionthat positive amyloid imaging in patients with MCI confers
a greater risk of progression in MMSE scores. Follow-up,
however, was limited to a period of 18 months, and there-
fore, further prospective longitudinal studies are required
to clarify this observation. It is also unknown whether the
sensitivity of amyloid imaging varies according to disease
stage. Duara et al. [30] found a lower rate of positive amyloid
scans among patients with MCI compared with those with
AD (50% vs. 93%). Without standardized SUVR reference
ranges or further studies assessing predementia phases of
AD, it is currently not possible to conclude whether disease
stage–specific SUVR thresholds are required to improve the
detection of early-phase AD.
The mean age of subjects with AD in the florbetapir, flor-
betaben, and flutemetamol groups was 72.5, 70.7, and
69.3 years, respectively. Results from this systematic review
and meta-analysis cannot, therefore, be easily extrapolated
for use of amyloid imaging in early-onset AD in whom
symptoms often present atypically including with aphasia,
apraxia, agnosia, and visual disturbance, rather than typical
amnestic syndromes. Predominant neocortical pathology,
sparing the hippocampi, may manifest with a different
pattern of biomarkers to disease in older age. The diagnostic
utility of amyloid imaging in early-onset disease, therefore,
requires separate investigation. Other areas requiring further
investigation are the effectiveness, including cost-
effectiveness, of amyloid imaging as compared to other
currently available diagnostic tools (including CSF bio-
markers, 18F-fluorodeoxyglucose positron emission
tomography, and single photon emission computed tomogra-
phy imaging), which are currently lacking.5. Conclusion
This systematic review and meta-analysis has demon-
strated favorable sensitivity and specificity of amyloid imag-
ing with novel fluorine tracers in diagnosis of AD,
supporting their use as an adjunct in clinical practice. It
has, however, also highlighted a number of areas of uncer-
tainty suggesting the need for further well-powered
J.M. Yeo et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 5–1312longitudinal studies including correctly phenotyped patients,
correlating with structural imaging and CSF biomarkers,
neuropsychology assessment, APOE ε4 status, and ulti-
mately, histopathological disease confirmation, before they
can be recommended for routine and widespread use.
Acknowledgments
S.P. is funded by a fellowship from NHS Research Scotland.
Supplementary data
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.dadm.2014.11.004.RESEARCH IN CONTEXT
1. Systematic review: We searched the Medical Litera-
ture Analysis and Retrieval System Online (MED-
LINE) and the Excerpta Medica Database
(EMBASE) for human studies published from
January 1980 to March 2014, inclusive of all lan-
guages. Search terms were “dementia”; “amyloid”
or “positron emission tomography”; “florbetapir” or
“florbetaben” or “flutemetamol”; “sensitivity” and
“specificity” or “diagnosis.” Articles fulfilling study
inclusion criteria were systematically evaluated us-
ing the STARD checklist.
2. Interpretation: To our knowledge, this is the first sys-
tematic review and meta-analysis investigating the
diagnostic utility of 18F-labeled tracers in Alz-
heimer’s disease (AD); our study demonstrated
favorable sensitivity and specificity, supporting their
use in clinical practice.
3. Future directions: Our study has highlighted areas of
uncertainty suggesting the need for well-powered
prospective studies with postmortem histopatholo-
gy as a diagnostic gold standard. Further investiga-
tion is required to evaluate uncertainties including,
whether APOE ε4 status influences imaging results
and if 18F imaging can successfully discriminate
between different dementias.
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